The Harry M. Zweig Memorial Fund for Equine Research

Reducing Equine Herpes Virus Viral Load and Recurrence through Epigenetic Control

Principal Investigator: Julia Felippe with Dr. Tallmadge
Contact Information: Email:; Phone: 607-253-3119
Project Costs: $58,702
Project Period: 1/1/2016-12/31/2016

Dr. Flippe Equine herpesvirus 1 (EHV1) is a ubiquitous and highly contagious pathogen that causes a range of disease severity from mild rhinopneumonitis to abortion, neurologic disease, and death. Notable outbreaks in recent years have emphasized the potential virulence of EHV1, the limitations of current vaccines, and ensuing economic impacts. The broad objective of this research is to identify treatments that will 1) significantly decrease EHV1 viral load, and consequent pathology and shedding during lytic infection; 2) complement antiviral drug efficacy during EHV1 infection; and 3) inhibit EHV1 reactivation from latency. The immediate objective of this project is to evaluate the potential of epigenetic drugs to modulate EHV1 infection because EHV1 gene expression is regulated by epigenetic mechanisms, primarily through histone modifications. Sustaining a repressive epigenetic state through inhibition of histone demethylation has been shown to effectively limit human a-herpesviruses in vitro and in vivo1-3. This outcome was observed both during lytic infection and reactivation from latency. Our hypothesis is that maintaining a repressive epigenetic state on the EHV1 genome will decrease viral load during lytic infection, and prevent reactivation from latency.